Scinai Immunotherapeutics
SCNI
17 hedge funds and large institutions have $20.8M invested in Scinai Immunotherapeutics in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 6 closing their positions.
81% more capital invested
Capital invested by funds: $11.5M → $20.8M (+$9.32M)
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
21% more funds holding
Funds holding: 14 → 17 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.71M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$764K |
| 3 |
State Street
Boston,
Massachusetts
|
+$633K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
+$330K |
| 5 |
MA
Mutual Advisors
Omaha,
Nebraska
|
+$276K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.22M |
| 2 |
VF
Virtu Financial
New York
|
-$260K |
| 3 |
II
Ibex Investors
Denver,
Colorado
|
-$234K |
| 4 |
BHB
Bank Hapoalim BM
Tel Aviv,
Israel
|
-$99.8K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$72.9K |
SCNI Hedge Fund Activity: Q3 2020 in Review
17 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2020, worth a combined $20.8M — up 81% from $11.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SCNI positions and 6 closed out — a net gain of 3 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.71M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.22M sold.
- 17 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2020, up from 14 in Q2 2020.
- Funds reported $20.8M of Scinai Immunotherapeutics stock for Q3 2020, up 81% quarter-over-quarter.
- 9 funds opened new Scinai Immunotherapeutics positions in Q3 2020 and 6 closed out, a net change of +3 holders.
- The largest Scinai Immunotherapeutics buyer in Q3 2020 was Morgan Stanley, an estimated $1.71M added.
- The largest Scinai Immunotherapeutics seller in Q3 2020 was Renaissance Technologies, an estimated $1.22M sold.
Based on aggregated 13F filings for Q3 2020.